Amgen recently announced its plans to submit a Marketing Authorization Application to the European Medicines Agency for teprotumumab, a fully human monoclonal antibody designed to treat moderate to severe Thyroid Eye Disease

Freedom Biosciences, Inc. has received notification from the U.S. Food and Drug Administration (FDA) greenlighting the initiation of its FREE001-TRD-201 study, a Phase 2a clinical trial for FREE001

Deverra Therapeutics, Inc., a biotechnology company specializing in developing advanced cell therapies for cancer and other serious diseases, has announced that the U.S. Food and Drug Administration

Ascendis Pharma A/S has announced that the Medicines & Healthcare Products Regulatory Agency in the United Kingdom has given the green light to YORVIPATH®. This marks a significant step forward as it's now authorized for treating adults

Tiziana Life Sciences, Ltd., a biotech company focused on developing innovative immunomodulation therapies through unique drug delivery methods, has received approval from the U.S. Food and Drug Administration

Acadia Pharmaceuticals Inc. has announced that Health Canada has accepted its New Drug Submission for trofinetide, a potential treatment for Rett syndrome, a rare neurodevelopmental disorder.

Immunovia has unveiled a significant advancement with its next-generation pancreatic cancer test, aimed at enhancing survival rates through early detection. The new test has successfully met primary and secondary endpoints

Ocugen, Inc., a biotechnology company specializing in gene and cell therapies as well as vaccines, has reported the completion of dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410

GenFleet Therapeutics, a leading biotechnology company specializing in advanced therapies for oncology and immunology, has received approval from the US Food and Drug Administration

Saghmos Therapeutics, Inc, a privately owned biopharmaceutical company, has revealed its collaboration with the Duke Clinical Research Institute (DCRI) to optimize and strategize the operationalization of its Phase 3 study